Cargando…

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

BACKGROUND: BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitations. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Heng, Li, Chenggong, Jiang, Huiwen, Zhao, Xinying, Huang, Zhiping, Jin, Dan, Guo, Tao, Kou, Haiming, Liu, Lin, Tang, Lu, Yin, Ping, Wang, Zhihui, Ai, Lisha, Ke, Sha, Xia, Yimeng, Deng, Jun, Chen, Lei, Cai, Li, Sun, Chunyan, Xia, Linghui, Hua, Gaoquan, Hu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501733/ https://www.ncbi.nlm.nih.gov/pubmed/34627333 http://dx.doi.org/10.1186/s13045-021-01170-7

Ejemplares similares

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Li, C., et al.
Publicado: (2022)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
por: Zah, Eugenia, et al.
Publicado: (2020)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
por: Wu, Lijun, et al.
Publicado: (2022)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
por: Foureau, David M., et al.
Publicado: (2020)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
por: Xia, Yuan, et al.
Publicado: (2023)

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma
por: Du, Mengyi, et al.
Publicado: (2022)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports
por: Xu, Jinhuan, et al.
Publicado: (2021)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
por: Wong, Sandy W., et al.
Publicado: (2021)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
por: Rejeski, Kai, et al.
Publicado: (2023)

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
por: Yan, Lingzhi, et al.
Publicado: (2020)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
por: Li, Chunrui, et al.
Publicado: (2021)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
por: Xu, Jinhuan, et al.
Publicado: (2018)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Qu, Xiaoyan, et al.
Publicado: (2022)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
por: Alabanza, Leah M., et al.
Publicado: (2022)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
por: Li, Dan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h47pdho7evbhts33ehctvh730q